Long-Term Efficacy of CDK4/6 Inhibitors in Premenopausal Women with Metastatic HR+/HER2- Breast Cancer
Professors Yeonhee Park, Heekyung Ahn, and Jiyeon Kim from Samsung Medical Center's Hematology and Oncology Department, along with Professor Seokah Lim from Seoul National University Hospital's Hematology and Oncology Department, and the Korean Cancer Research Association's Breast Cancer Research Team, recently announced the overall survival results of Phase 2 clinical trial of the Young-PEARL study in the renowned cancer journal The Lancet Oncology (Impact Factor: 41.6). This marks the second publication following their 2019 study.
The study found that the combination of palbociclib (a CDK4/6 inhibitor) and hormone therapy (exemestane, leuprorelin) resulted in a longer progression-free survival and fewer side effects, ultimately improving the quality of life compared to traditional cytotoxic chemotherapy (capecitabine).
This study is expected to establish a new standard strategy for treating premenopausal breast cancer. The research team believes it is highly likely to influence future changes in global treatment guidelines.